OBJECTIVE: In patients with axillary metastases as clinical evidence of possible occult breast cancer, a combined approach of MR imaging, sonography, and aspiration biopsy cytology was evaluated. SUBJECTS AND METHODS: Thirty-one women with metastatic adenocarcinoma in their axillary lymph nodes originating from an unknown primary site underwent MR imaging of the breast because physical examination and mammography findings were normal. Twenty of the 31 women had no history of malignancy, 10 had been previously treated for contralateral breast cancer, and one patient had nodal metastases in the contralateral axilla at the time breast cancer was detected. When a contrast-enhancing lesion was revealed on MR imaging of the breast, sonography and fine-needle aspiration cytology were also performed. RESULTS: MR imaging revealed the primary breast cancer in eight (40%) of the 20 patients without a history of malignancy. MR imaging of the breast revealed a second primary cancer in three (27%) of the 11 patients with previous or simultaneous breast cancer. All lesions were identified with sonography and verified by cytology and histology. CONCLUSION: In women with axillary lymph node metastases from adenocarcinoma, MR imaging of the breast should be added to clinical examination and mammography before defining the breast cancer as occult. The combined approach of MR imaging, sonography, and aspiration fine-needle cytology is a good alternative to the MR imaging-guided biopsy.
OBJECTIVE: In patients with axillary metastases as clinical evidence of possible occult breast cancer, a combined approach of MR imaging, sonography, and aspiration biopsy cytology was evaluated. SUBJECTS AND METHODS: Thirty-one women with metastatic adenocarcinoma in their axillary lymph nodes originating from an unknown primary site underwent MR imaging of the breast because physical examination and mammography findings were normal. Twenty of the 31 women had no history of malignancy, 10 had been previously treated for contralateral breast cancer, and one patient had nodal metastases in the contralateral axilla at the time breast cancer was detected. When a contrast-enhancing lesion was revealed on MR imaging of the breast, sonography and fine-needle aspiration cytology were also performed. RESULTS: MR imaging revealed the primary breast cancer in eight (40%) of the 20 patients without a history of malignancy. MR imaging of the breast revealed a second primary cancer in three (27%) of the 11 patients with previous or simultaneous breast cancer. All lesions were identified with sonography and verified by cytology and histology. CONCLUSION: In women with axillary lymph node metastases from adenocarcinoma, MR imaging of the breast should be added to clinical examination and mammography before defining the breast cancer as occult. The combined approach of MR imaging, sonography, and aspiration fine-needle cytology is a good alternative to the MR imaging-guided biopsy.
Authors: Elena Belloni; Pietro Panizza; Silvia Ravelli; Francesco De Cobelli; Simone Gusmini; Claudio Losio; Isabella Sassi; Gianluca Perseghin; Alessandro Del Maschio Journal: Radiol Med Date: 2013-06-25 Impact factor: 3.469
Authors: Oluwadamilola M Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Donna B Jeffe; Julie A Margenthaler Journal: Ann Surg Oncol Date: 2013-08-22 Impact factor: 5.344
Authors: Wendy B DeMartini; Laura Ichikawa; Bonnie C Yankaskas; Diana Buist; Karla Kerlikowske; Berta Geller; Tracy Onega; Robert D Rosenberg; Constance D Lehman Journal: J Am Coll Radiol Date: 2010-11 Impact factor: 5.532
Authors: Wendy B Demartini; Brenda F Kurland; Robert L Gutierrez; C Craig Blackmore; Sue Peacock; Constance D Lehman Journal: Eur Radiol Date: 2011-02-27 Impact factor: 5.315
Authors: Wendy B DeMartini; Lucy Hanna; Constantine Gatsonis; Mary C Mahoney; Constance D Lehman Journal: AJR Am J Roentgenol Date: 2012-09 Impact factor: 3.959
Authors: Katrien Schelfout; E Kersschot; M Van Goethem; L Thienpont; J Van den Haute; A Roelstraete; A De Schepper Journal: Eur Radiol Date: 2002-11-19 Impact factor: 5.315